STOCK TITAN

Crescent Biopharma: BVF reports roughly 9.8% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Crescent Biopharma, Inc. (CBIO) ownership disclosures state that BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., may each be deemed to beneficially own 3,691,518 ordinary shares, approximately 9.8%, as of September 30, 2026. These are overlapping attributions to the same aggregate position, not separate holdings to add. Biotechnology Value Fund, L.P. reported 1,937,712 shares (5.2%); Biotechnology Value Fund II, L.P. reported 1,453,037 (3.9%); and Biotechnology Value Trading Fund OS LP reported 244,187 (less than 1%).

The reporting persons and a Partners-managed account held pre-funded warrants exercisable for an aggregate 597,928 shares at $0.001 per share, with no expiration. The 9.99% ownership blocker did not limit exercise as of September 30, 2026. The reported ownership percentages use 37,143,940 ordinary shares outstanding as of July 27, 2026, plus 597,928 shares issuable upon warrant exercise, as the denominator.

Beneficial ownership attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 3,691,518 shares Each may be deemed to beneficially own the same aggregate position as of September 30, 2026.
Reported beneficial ownership percentage Approximately 9.8% Percentage reported for BVF Partners L.P., BVF Inc. and Mark N. Lampert as of September 30, 2026.
Pre-funded warrants 597,928 shares Aggregate shares issuable upon exercise of warrants held by the reporting persons and a Partners-managed account.
Warrant exercise price $0.001 per share Exercise price for the pre-funded warrants.
Ownership blocker 9.99% Limits warrant exercise where it would cause beneficial ownership to exceed the stated threshold; it did not limit exercise as of September 30, 2026.
Ordinary shares outstanding 37,143,940 shares As of July 27, 2026; used with 597,928 warrant shares in the reported percentage denominator.
Biotechnology Value Fund, L.P. beneficial ownership 1,937,712 shares Approximately 5.2% as of September 30, 2026.
Biotechnology Value Fund II, L.P. beneficial ownership 1,453,037 shares Approximately 3.9% as of September 30, 2026.
beneficially own financial
"may be deemed to beneficially own the 3,691,518 Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Pre-Funded Warrants financial
"Pre-Funded Warrants exercisable for an aggregate of 597,928 Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Pre-Funded Warrants Blocker regulatory
"the Pre-Funded Warrants Blocker does not limit the exercise"
Attribution Parties regulatory
"holder, together with its Attribution Parties"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of CBIO's pre-funded warrants?

The reporting persons and a Partners-managed account held warrants exercisable for an aggregate 597,928 ordinary shares at $0.001 per share, with no expiration. A 9.99% ownership blocker applies, and it did not limit exercise as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G2545C104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading